GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Purchased by Savant Capital LLC

Savant Capital LLC boosted its position in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 149.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 27,585 shares of the company’s stock after acquiring an additional 16,538 shares during the quarter. Savant Capital LLC’s holdings in GE HealthCare Technologies were worth $2,157,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in shares of GE HealthCare Technologies by 7.8% in the third quarter. State Street Corp now owns 18,615,890 shares of the company’s stock worth $1,747,101,000 after purchasing an additional 1,347,114 shares during the last quarter. Geode Capital Management LLC raised its position in GE HealthCare Technologies by 7.2% during the 3rd quarter. Geode Capital Management LLC now owns 10,977,757 shares of the company’s stock worth $1,026,898,000 after buying an additional 733,819 shares during the last quarter. D1 Capital Partners L.P. purchased a new position in GE HealthCare Technologies during the 3rd quarter worth approximately $268,159,000. Charles Schwab Investment Management Inc. lifted its stake in GE HealthCare Technologies by 12.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,710,938 shares of the company’s stock valued at $254,422,000 after acquiring an additional 290,019 shares during the period. Finally, Van ECK Associates Corp purchased a new stake in shares of GE HealthCare Technologies in the 3rd quarter valued at $208,513,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Jefferies Financial Group upgraded shares of GE HealthCare Technologies from a “hold” rating to a “buy” rating and boosted their target price for the company from $95.00 to $103.00 in a research report on Wednesday, January 8th. Wells Fargo & Company lifted their price objective on GE HealthCare Technologies from $95.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $96.77.

GE HealthCare Technologies Stock Performance

NASDAQ GEHC opened at $85.90 on Thursday. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. GE HealthCare Technologies Inc. has a twelve month low of $74.51 and a twelve month high of $94.55. The stock has a 50-day moving average of $83.58 and a 200 day moving average of $85.39. The stock has a market capitalization of $39.25 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.93 and a beta of 1.15.

GE HealthCare Technologies Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a dividend of $0.035 per share. This is a positive change from GE HealthCare Technologies’s previous quarterly dividend of $0.03. The ex-dividend date is Tuesday, January 14th. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.16%. GE HealthCare Technologies’s dividend payout ratio (DPR) is 3.85%.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.